Future Research
Simmaron is currently raising funds for two new studies to scientifically redefine ME/CFS.
Your contributions can expand our ability to execute the strong scientific leads we already have.
Simmaron has two exciting funding priorities to help scientifically redefine ME/CFS:
- Arthropod-Borne Disease in Post-Infectious Fatigue: Simmaron has been awarded access to samples from the NIH directed XMRV investigation to study the presence of antibodies to vector-borne pathogens in 293 highly characterized CFS/ME patients and controls. This study will assess the similarities and differences in exposure to multiple tick and mosquito-borne pathogens among this geographically diverse patient cohort, with the potential to aid in subsetting and identifying a role of infection in precipitating CFS/ME.
Collaborators: Wisconsin Viral, Sierra Internal Medicine
Cost: $300,000
- Assessment of the prevalence of clonal T-cell receptor gamma gene rearrangements in CFS patients with herpes virus infections: Simmaron will assess the diagnostic and prognostic potential value of analyzing CFS/ME patients for T-cell receptor gamma clonality. As CFS/ME is associated with increased incidence of lymphoma and certain other cancers, this study will investigate the value of T-cell gene rearrangements in identifying a subset of patients who are at risk of developing cancer, for diagnostic and treatment purposes.
Collaborators: University of Nevada, Reno, Sierra Internal Medicine
Cost: $152,000
Simmaron is the only non-governmental investigator awarded samples from the NIH XMRV study to date! This unique opportunity must be funded to proceed, and we need your help.
Simmaron is also the only ME/CFS research organization in the US seeking to answer WHY ME/CFS patients have a higher incidence of cancer, that we know of.
Donate as we scientifically redefine ME/CFS!
